anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All participants in the enhanced usual care arm must own a cell phone with at least short message service (SMS) and voicemail. To control for attention exposure, they will receive SMS messages daily dealing with healthy lifestyle behaviors (smoking, diet, physical activity) but not with medication adherence or hypertension-specific issues. Every three days (comparable to intervention group monitoring) they will receive an automated SMS directing them to a different 2-3 min video/YouTube™ clips on healthy lifestyles. Patients in this arm of the study will also receive usual care as determined by their providers. Usual care is described in the next section.
The patients were managed to achieve similar goals: MAP 65-90 mmHg; urine output ≥ 0.5 mL·kg-1·h-1; SpO2 \> 95%; and hematocrit 26-30%, using information from the FloTrac/EV1000. The EGDT group received: fluid to maintain a SVV \< 13%; inotropic drugs to achieve a SVI of 33-65 mL·beat-1·m-2 and CI of 2.2-4.0 L·min-1·m-2; and/or vasoactive drugs to achieve a SVRI of 1600-2500 dynes·s·cm-5·m-2. ABG and electrolytes were monitored and corrected in the same manner.
Endomucin (MUC14), encoded by EMCN gene, is an O-glycosylated transmembrane mucin that is mainly found in venous endothelial cells (ECs) and highly expressed in type H vessels of bone tissue. Its main biological functions include promoting endothelial generation and migration through the vascular endothelial growth factor (VEGF) signaling pathway and inhibiting the adhesion of inflammatory cells to ECs. In addition, it induces angiogenesis and promotes bone formation. Due to the excellent functions of Endomucin in the above aspects, it provides a new research target for the treatment of vascular inflammatory-related diseases and bone diseases. Based on the current understanding of its function, the research of Endomucin mainly focuses on the above two diseases. As it is known, the progression of cancer is closely related to angiogenesis. Endomucin recently is found to be differentially expressed in a variety of tumors and correlated with survival rate. The biological role of Endomucin in cancer is opaque. This article introduces the research progress of Endomucin in vascular inflammatory-related diseases and bone diseases, discusses its application value and prospect in the treatment, and collects the latest research situation of Endomucin in tumors, to provide meaningful evidence for expanding the research field of Endomucin.
Patients receive veliparib PO BID on days 1-14 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
An antibody is claimed which binds selectively to a characteristic marker epitope of an oncogene prod., which epitope is not present in the corresp. proto-oncogene prod. Pref. the oncogene prod. is an activated form of P21 protein and the epitope encompasses position 12. Also claimed is a method for detecting a polypeptide or an oncogene prod. In a celluar sample of a patient, the polypeptide having a characteristic marker epitope which is not exposed in the undenatured polypeptide and the oncogene prod. having a characteristic marker epitope which is not present in the proto- oncogene prod. and which is not exposed in the undenatured protein.
The present invention relates to a stable pharmaceutical formulation of a pharmaceutically active anti-cd20 antibody such as e.g. BVX20 for intravenous (IV) administration. The formulation of the present invention is found to be stable for up to 24 months at 2-8°C. In particular, the present invention relates to single-dose formulation comprising, a suitable amount of the anti-cd20 antibody as active ingredient, an effective amount of buffering agent, such as e.g. a L-histidine buffer and a surfactant such as e.g. polysorbate 80.
Imatinib is the current gold standard for patients with chronic myeloid leukemia (CML). However, the primary and acquired drug resistance seriously limits the efficacy. To identify novel therapeutic target in Imatinib-resistant CML is of crucial clinical significance. CircRNAs have been demonstrated the essential regulatory roles in the progression and drug resistance of cancers. In this study, we identified a novel circRNA (circ_SIRT1), derived from the SIRT1, which is up-regulated in CML. The high expression of circ_SIRT1 is correlated with drug resistance in CML. Knockdown of circ_SIRT1 regulated K562/R cells viability, invasion and apoptosis. Besides, the inhibition of circ_SIRT1 attenuated autophagy level and reduced IC50 to Imatinib of K562/R cells. Mechanistically, circ_SIRT1 directly binds to the transcription factor Eukaryotic Translation Initiation Factor 4A3(EIF4A3) and regulated EIF4A3-mediated transcription of Autophagy Related 12 (ATG12), thereby affecting Imatinib resistance and autophagy level. Overexpression of ATG12 reversed the regulative effects induced by knockdown of circ_SIRT1. Taken together, our findings revealed circ_SIRT1 acted as a potential tumor regulator in CML and unveiled the underlying mechanism on regulating Imatinib resistance. circ_SIRT1 may serve as a novel therapeutic target and provide crucial clinical implications for Imatinib-resistant CML treatment.
Cosmetic compsns. consisting of fatty and powdered components comprise particles of surface-stabilised polymer dispersed in a fatty liq. medium. The liq. fatty medium is pref. chosen from non aq. liq. compsns. with an overall solubility parameter in the HANSEN interval of solubility of <17 (MPa)1/2; and/or monoalcohols with an overall solubility parameter in the HANSEN interval of solubility of <20 (MPa)1/2. The liq. fatty medium is selected from wax, oils, rubber and/or fatty greasy components which are silicon-base or of mineral, animal, plant and synthetic origin, fatty liquids include e.g. paraffin oil, vaseline or soya oil. The polymer may be a radical polymer, a polycondensate and/or a naturally occuring polymer. The polymer particles are surface stabilised by a sequenced polymer, a graft polymer and/or a statistical polymer.
DV is given intravenously once every 2 weeks, (dose escalation plan: 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg). DV will be administered at least 2 times during the treatment, and the final DV dose needs to be completed before the last radiotherapy.
Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone - This study will be conducted as an open-label Phase I/II, single-center study in which subjects will receive carfilzomib, lenalidomide, vorinostat and dexamethasone, for relapsed and/or refractory multiple myeloma. Study treatment will be administered in sequential cohorts, with 3-6 subjects in each cohort. Treatment will be administered in 28-day cycles, with the fourth week as a rest week, for 12 cycles or until disease progression or unacceptable toxicity develops.
The invention discloses a traditional Chinese medicine composition for treating open small wounds and traumatic injury. The traditional Chinese medicine composition refers to externally applied plaster (triple-effect plaster for short). The plaster consists of 20 traditional Chinese medicines such as dragon's blood, cutch, huechys, scorpio, centipede, garter snake, Angelica sinensis, honeysuckle, root of rehmannia, Bletilla, monkshood, radix aconiti agrestis, spina gleditsiae, nux vomica, notopterygium root, frankincense, myrrh, carbonized hair, minium and sesame oil. The traditional Chinese medicine composition disclosed by the invention has the effects of promoting blood circulation to remove blood stasis, eliminating stagnation and promoting regeneration, regenerating tissue to heal wound, dissipating stasis and relieving pain, stopping bleeding, activating meridians to stop pain, as well as removing stasis and removing toxins and is used for treating traumatic injury, carbuncle, sore-toxins and stubborn dermatitis; the whole medicines are compatible and have the effects of clearing away heat and toxic materials, relieving swelling and pain, removing slough and promoting growth of tissue regeneration and clearing and activating the channels and collaterals. The most important is that the traditional Chinese medicine externally applied plaster disclosed by the invention has the advantages that a phenomenon that active ingredients of the medicines are fried by using high-temperature oil like a traditional black plaster is avoided, while raw medicine powder is totally added into a plaster matrix, the active ingredients of the medicines are not damaged by high temperature, and total active ingredients of the raw medicines are maintained. Therefore, the drug efficacy is greatly improved, which is the advantage of the traditional Chinese medicine composition.
Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
The invention provides high-functional antibody biological synthesis, and particularly provides a novel screening method of a recombinant antibody. The method applies a repeated circulating process, namely gene bank diversification, protein expression and function screening, until a satisfied antibody is obtained. When the antibody is expressed, a multipurpose polypeptide sequence (Tag) is connected to the C end of the antibody; and by the polypeptide sequence, a dipolymer (scFv)2 can be formed by a single-chain antibody (scFv), and the affinity of the antibody is further enhanced. The polypeptide sequence can be used for marking, purifying and detecting the antibody. By adopting the method, certain anti-CEA (carcinoembryonic antigen) single-chain antibodies can be successfully obtained, and one antibody can be directly developed into a diagnosis and treatment reagent. The antibodies can provide a useful CDRs (complementarity determining region) bank, and the required high-activity CEA antibody is produced by virtue of sequence recombination.
Three different types of experiments will be performed:

(A). Testing of Cross corrections breathing air at 8,000 (0.743 ATA) and 10,000 ft (0.688 ATA). Subjects will be decompressed in a hypobaric chamber to one of the altitudes above. A no-stop dive to 60 fsw will be tested at each altitude (2.82 ATA at sea level, 2.56 ATA at 8,000 ft, 2.51 ATA at 10,000 ft). Using the Cross corrections, the virtual depth for both altitudes is 90 fsw, for which the no-stop time is 30 minutes. During the dive the subject will be immersed/submersed at rest/mild exercise in 28°C water. Ascent rate will be 30 fsw/min. Upon surfacing the diver will be monitored for 12 hours for symptoms of decompression sickness and transthoracic echocardiography (rest and leg/arm motion) to examine for venous gas embolism (VGE) at 5, 15, 30, 60 and 120 minutes after surfacing. After that, measurements will be continued until no bubbles are detected.

(B). Testing of a no-stop dive to 100 fsw at 10,000 ft and 12,000 ft breathing 35% O2. For this series of experiments all subjects will remain at altitude for 48 hours before diving, in order to allow for resolution of AMS symptoms. Appropriate depth-time profiles have been assessed by calculating the equivalent sea level air depth for each of these dives (PN2 values 2.42 and 2.36 ATM, respectively). These yield equivalent air depths of 68 and 66 fsw, respectively. Cross corrected virtual depths would therefore be 99 and 104 fsw, yielding no-stop times of 25 and 20 minutes, respectively. The Cross correction method will be used in this instance because, although largely untested, it is presently in use by the Navy. As with the air dives described above, the more provocative dives (12,000 ft) will be completed before the ones at 10,000 ft, which will increase the confidence for the bottom time used at the lower altitude.

(C). Testing to determine whether a high PO2 dive would reverse altitude acclimatization and re-establish susceptibility to AMS. Subjects will ascend in the chamber to 15,000 ft in a graded fashion over 12 hours (15,000 ft has been chosen due to extensive Duke experience with this altitude). Then, after 48 hours they will simulate a hyperoxic dive by breathing 100% O2 for 120 minutes at 1.3 ATA. This will simulate, for example, a 2 hour dive at 12,000 ft to 65 fsw breathing 50% O2. The diver will then return to 15,000 ft and remain at that altitude for 24 hours to allow for AMS symptoms to recur (if indeed they do). Lake Louise AMS scores will be collected every 8 hours. AMS symptoms will be treated with acetaminophen, NSAIDs and anti-emetics as needed. Subjects will be assessed clinically every 12 hours for high altitude pulmonary edema (HAPE) and high altitude cerebral edema (HACE). Occurrence of either HAPE or HACE will require that the subject be returned immediately to 1 ATA and treated appropriately.
Intercellular adhesion molecule 1 (ICAM-1/CD54), a transmembrane glycoprotein, has been considered as one of the most important adhesion molecules during leukocyte recruitment. It is encoded by the ICAM1 gene and plays a central role in inflammation. Its crucial role in many inflammatory diseases such as ulcerative colitis and rheumatoid arthritis are well established. Given that neuroinflammation, underscored by microglial activation, is a key element in neurodegenerative diseases such as Parkinson's disease (PD), we investigated whether ICAM-1 has a role in this progressive neurological condition and, if so, to elucidate the underpinning mechanisms. Specifically, we were interested in the potential interaction between ICAM-1, glial cells, and ferroptosis, an iron-dependent form of cell death that has recently been implicated in PD. We conclude that there exist direct and indirect (via glial cells and T cells) influences of ICAM-1 on ferroptosis and that further elucidation of these interactions can suggest novel intervention for this devastating disease.
The investigators will conduct a double-blind randomized controlled trial to compare hs-CRP and hs-Troponin levels between prilocaine 2% and hyperbaric lidocaine 5% in adult patients undergoing cystoscopy procedure with spinal anesthesia. This study was approved by the Health Research Ethics Committee (Institutional Review Board) of Dr. Moewardi General Hospital Surakarta. Before randomization, participants who are eligible based on inclusion and exclusion criteria will be given informed consent. If the patients agree, the patient will be included in this research. Ninety adult patients will be randomly divided into control group and treatment group. Control group (group L) will be given 1 mL hyperbaric lidocaine 5% (50 mg) and treatment group (group P) will be given 2.5 mL prilocaine 2% (50 mg) as spinal anesthesia. The investigators will measure hs-CRP serum levels and hs-Troponin serum levels as the primary outcome. Serum levels of hs-CRP dan hs-Troponin will be measured 4 hours postoperative.
This is a double-blind (neither physician nor participants knows the treatment that the participant receives), randomized (study medication is assigned by chance), placebo-controlled (an inactive substance is compared with a medication to test whether the medication has a real effect in a clinical study), single- and multiple ascending dose study. This study consists of 3 phases: screening phase, treatment phase, and follow-up phase. This study will be conducted in 2 cohorts (groups) (Cohort 1: JNJ-40411813 50 mg and Cohort 2: JNJ-40411813 100 mg) and each cohort consists of 2 periods (Period 1: single dose and Period 2: multiple doses). Approximately 36 participants will be enrolled in this study (18 participants will be enrolled in each cohort) to receive JNJ-40411813 or placebo in 2:1 ratio. If safety/tolerability and pharmacokinetic results profile is favorable for single dose of JNJ-40411813, multiple dose administration will follow. Safety will be evaluated by the assessment of adverse events, vital signs, schellong test (a test for circulatory function), 12-lead electrocardiogram, physical examination, neurological examination (to measure mental status, motor examination, reflexes, sensory, gait and cranial nerves), vertigo (giddiness) symptom, and clinical laboratory tests which will be monitored throughout the study. The total duration of study participation for a participant will be 9 weeks.
NEW MATERIAL:3-Acyloxy-4(H)-pyran-4-one of formulaI(R is CH3, C15H31 or C17H35). EXAMPLE:3-Acetoyloxy-4(H)-pyran-4-one. USE:A kin beautifying agent or a bleaching agent for external use. It has high chemical stability. The chelation of the compound with metals such as iron effects  no color development, but increases the solubility in fat and improves the absorptivity through the skin. PROCESS:The compound of formulaIis prepared by reacting the compound of formula II with the corresponding acyl halide using a conventional process. When  the compound of formulaIis absorbed in the skin, it is immediately hydrolyzed to  the compound of formula II, which exhibits tyrosinase activity inhibiting action, suppresses the formation of melamine, and gives skin beautifying effecr even to human body. The amount of the compound in the skin beautifying cosmetic or the bleaching agent for external use is 0.002-5wt%, pref. 0.01-1wt%.
Stable pharmaceutical solns. contain a hydrogenated rye ergot alkaloid (I) or one of its salts, and heparin (II) or one of its salts, together with a stabilising medium (where R is H or 1-4C alkyl; R1 is methyl, ethyl or isopropyl; R2 is isopropyl, sec.-butyl, isobutyl or benzyl; and X is H or OMe). The stabilising medium is a mixt. of water and aliphatic mono- or polyols together with an N-acylated aniline, and urea and/or calcium EDTA salt. Previous combinations of (I) and (II) tend to form an insoluble salt on storage. The new solns. do not suffer from this drawback and can be stored, then given by innection.
[EP0028813A2]
Participants assigned to Tr1 will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
The invention discloses a mimic epitope peptide, the amino acid sequence of which is shown as SEQ NO. 1. The invention also provides a gene for coding the mimic epitope peptide. The invention also provides a polyclonal antibody, which is prepared by immunizing animals by using the mimic epitope peptide as an antigen. The invention also provides the application of the mimotope peptide and the polyclonal antibody in the preparation of medicines for preventing and/or treating chronic fibrosis diseases. The medicine of the invention can relieve renal fibrosis by inhibiting IL-6 signals and tissue iron death. After the mimic epitope peptide is applied to a mouse renal fibrosis model constructed by a unilateral ureteral ligation method, MASSON shows that the mouse renal fibrosis degree is remarkably relieved, immunohistochemical experiments indicate that the expression of fibrosis-related proteins in renal tissues is remarkably reduced, the number of macrophages in the renal tissues and spleen is remarkably reduced, and IL-6 signals and iron death signal channels of the mouse renal tissues are inhibited.
Solubilizing, or improving solubility of, a peptide (I) in aqueous medium comprising covalent attachment of at least 3 residues of Arg and/or Lys, provided at least one is Arg, in L or D form, distributed over the N and/or C termini in the form of a linear or branched chain, is new. Independent claims are also included for: (1) peptide ligand (Ia) of MHC (major histocompatibility complex) modified by attachment of at least 3 residues of Arg and/or Lys, provided at least one is Arg, in L or D form, distributed over the N and/or C termini in the form of a linear or branched chain; and (2) vaccine containing at least one peptide that contains at least one hydrophobic epitope derived from an antigenic protein of a microbial pathogen or tumor and modified by the new method or is (Ia). ACTIVITY : Virucide; Antibacterial; Parasiticide; Fungicide; Cytostatic. The modified melanoma Melan/Mart-1 peptide (4R-ELA) of sequence (Arg)4-Glu-Leu-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val was administered (50 Microg plus 300 Microg of the P40 adjuvant) subcutaneously to mice. Ten days later, spleen cells were recovered and cultured in presence of interleukin-2 and of fixed antigen-presenting cells loaded with ELA. The effector cells were restimulated after 7 days, then after a further 5 days they were tested in a chromium release assay against EL4 A2/kb cells loaded with peptide. At an effector:target ratio 100, the specific lysis was over 80%. MECHANISM OF ACTION : Vaccine; Gene Therapy.
INTRODUCTION: Preeclampsia (PE) is a severe obstetrical syndrome characterized by new-onset hypertension and proteinuria and it is often associated with fetal intrauterine growth restriction (IUGR). PE leads to long-term health complications, so early diagnosis would be crucial for timely prevention. There are multiple etiologies and subtypes of PE, and this heterogeneity has hindered accurate identification in the presymptomatic phase. Recent investigations have pointed to the potential role of small regulatory RNAs in PE, and these species, which travel in extracellular vesicles (EVs) in the circulation, have raised the possibility of non-invasive diagnostics. The aim of this study was to investigate the behavior of exosomal regulatory small RNAs in the most severe subtype of PE with IUGR.
METHODS: We isolated exosomal EVs from first-trimester peripheral blood plasma samples of women who later developed preterm PE with IUGR (n=6) and gestational age-matched healthy controls (n=14). The small RNA content of EVs and their differential expression were determined by next-generation sequencing and further validated by quantitative real-time PCR. We also applied the rigorous exceRpt bioinformatics pipeline for small RNA identification, followed by target verification and Gene Ontology analysis.
RESULTS: Overall, >2700 small RNAs were identified in all samples and, of interest, the majority belonged to the RNA interference (RNAi) pathways. Among the RNAi species, 16 differentially expressed microRNAs were up-regulated in PE, whereas up-regulated and down-regulated members were equally found among the six identified Piwi-associated RNAs. Gene ontology analysis of the predicted small RNA targets showed enrichment of genes in pathways related to immune processes involved in decidualization, placentation and embryonic development, indicating that dysregulation of the induced small RNAs is connected to the impairment of immune pathways in preeclampsia development. Finally, the subsequent validation experiments revealed that the hsa_piR_016658 piRNA is a promising biomarker candidate for preterm PE associated with IUGR.
DISCUSSION: Our rigorously designed study in a homogeneous group of patients unraveled small RNAs in circulating maternal exosomes that act on physiological pathways dysregulated in preterm PE with IUGR. Therefore, our small RNA hits are not only suitable biomarker candidates, but the revealed biological pathways may further inform us about the complex pathology of this severe PE subtype.